Jonathan Graham - Amgen Insider

Amgen Inc -- USA Stock  

USD 192.33  3.05  1.61%

Senior Vice President General Counsel, Secretary

Mr. Jonathan P. Graham is Senior Vice President, General Counsel, Secretary of the Company. Prior to joining the Company, From July 2006 to May 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporationrationration. From October 2004 to June 2006, Mr. Graham was Vice President, Litigation and Legal Policy at General Electric Company . Prior to GE, Mr. Graham was a partner at Williams Connolly LLP.
Age: 55  President Since 2015      
805 447-1010  www.amgen.com

Jonathan Graham Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.92 % which means that it generated profit of $7.92 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 25.96 % meaning that it created $25.96 on every $100 dollars invested by stockholders.
The company currently holds 35.78 B in liabilities with Debt to Equity (D/E) ratio of 111.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Joseph ManningAbbott Laboratories
2017
Robert FordAbbott Laboratories
2015
Antonio PeraEndo International plc
2016
Brian LortieEndo International plc
N/A
JeanYves PaveeAbbott Laboratories
2015
Jaime ContrerasAbbott Laboratories
2013
Georges VosAbbott Laboratories
2013
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Wayne SwantonAllergan plc
2017
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Charles FoltzAbbott Laboratories
2013
Jared WatkinAbbott Laboratories
2015
Paul SilvaVertex Pharmaceuticals Incorpor
2011
Paul NavarreAllergan plc
Matthew MalettaEndo International plc
2015
Michael RousseauAbbott Laboratories
2017
Shannon HallBio Rad Laboratories Inc
2014
Michael WarmuthAbbott Laboratories
2012
Shawn SoderbergBio Rad Laboratories Inc
2013
Camille FarhatEndo International plc
2012
Murthy SimhambhatlaAbbott Laboratories
2013

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Price Exposure Probability Now
   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
Hide  View All  NextLaunch Price Exposure Probability
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators